gemcitabine has been researched along with tamibarotene in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Enomoto, A; Fujishiro, M; Iida, T; Imai, M; Ishikawa, T; Kawashima, H; Kinoshita, F; Kuwatsuka, Y; Mizutani, Y; Ohno, E; Shimizu, S; Tsuruta, T | 1 |
1 trial(s) available for gemcitabine and tamibarotene
| Article | Year |
|---|---|
Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Biomarkers, Tumor; Cancer-Associated Fibroblasts; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Repositioning; Female; Gemcitabine; Humans; Immunoglobulins; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Stromal Cells; Tetrahydronaphthalenes; Treatment Outcome; Tumor Microenvironment; Young Adult | 2022 |